Insider Transactions in Q1 2021 at Dexcom Inc (DXCM)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.47%
|
$175,000
$350.0 P/Share
|
|
Mar 23
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,109
-2.99%
|
$398,131
$359.03 P/Share
|
|
Mar 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.39%
|
$386,282
$358.91 P/Share
|
|
Mar 18
2021
|
Nicholas Augustinos Director |
SELL
Other acquisition or disposition
|
Indirect |
2,192
-21.72%
|
-
|
|
Mar 18
2021
|
Nicholas Augustinos Director |
BUY
Other acquisition or disposition
|
Direct |
2,192
+42.24%
|
-
|
|
Mar 11
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
1,867
-10.37%
|
$662,785
$355.86 P/Share
|
|
Mar 10
2021
|
Donald Abbey EVP Global Business Services I |
SELL
Open market or private sale
|
Direct |
5,566
-10.03%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Direct |
5,566
-13.62%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,509
-12.6%
|
$2,356,258
$362.22 P/Share
|
|
Mar 10
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,353
-4.83%
|
$1,937,786
$362.92 P/Share
|
|
Mar 10
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,471
-14.64%
|
$1,256,502
$362.92 P/Share
|
|
Mar 10
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
5,566
-9.11%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
14,044
-10.68%
|
$5,083,928
$362.92 P/Share
|
|
Mar 10
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,700
-13.04%
|
$977,400
$362.92 P/Share
|
|
Mar 10
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
941
-5.86%
|
$340,642
$362.92 P/Share
|
|
Mar 09
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
3,857
-0.41%
|
$1,388,520
$360.86 P/Share
|
|
Mar 09
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
152
-0.73%
|
$54,112
$356.94 P/Share
|
|
Mar 08
2021
|
Donald Abbey EVP Global Business Services I |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+8.72%
|
-
|
|
Mar 08
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+11.48%
|
-
|
|
Mar 08
2021
|
Quentin S. Blackford Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,491
+12.66%
|
-
|
|
Mar 08
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,634
+19.2%
|
-
|
|
Mar 08
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+7.98%
|
-
|
|
Mar 08
2021
|
Barry J. Regan EVP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+28.18%
|
-
|
|
Mar 08
2021
|
Kevin R Sayer President CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
13,445
+9.03%
|
-
|
|
Mar 08
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,073
+12.84%
|
-
|
|
Mar 08
2021
|
Sadie Stern EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,634
+28.93%
|
-
|
|
Mar 08
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+24.83%
|
-
|
|
Mar 08
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,171
+6.08%
|
-
|
|
Feb 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.69%
|
$198,000
$396.79 P/Share
|
|
Feb 24
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-12.51%
|
$448,440
$404.0 P/Share
|
|
Feb 24
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-5.31%
|
$242,400
$404.0 P/Share
|
|
Feb 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-1.9%
|
$438,074
$406.98 P/Share
|
|
Feb 19
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,800
-3.07%
|
$756,000
$420.01 P/Share
|
|
Feb 17
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Bona fide gift
|
Direct |
10,000
-7.58%
|
-
|
|
Feb 16
2021
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
1,875
-15.67%
|
$772,500
$412.03 P/Share
|
|
Feb 01
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
12,468
-1.28%
|
$4,687,968
$376.93 P/Share
|
|
Jan 27
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.62%
|
$179,500
$359.7 P/Share
|
|
Jan 22
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-2.32%
|
$409,590
$369.45 P/Share
|
|
Jan 22
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.45%
|
$398,151
$369.77 P/Share
|
|
Jan 13
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
7,073
-0.68%
|
$2,510,915
$355.05 P/Share
|
|
Jan 12
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
39,949
-10.46%
|
$14,381,640
$360.9 P/Share
|
|
Jan 08
2021
|
Kevin R Sayer President CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
75,910
+28.4%
|
-
|
|
Jan 06
2021
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
625
-4.96%
|
$234,375
$375.0 P/Share
|
|
Jan 04
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,025
-11.31%
|
$4,013,100
$364.73 P/Share
|